ALEC

MKT CAP:$271M

Alector, Inc.

Market Cap

$271M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$2.43+$0.90 (+58.82%)

Apr 23, 2026

Company Details

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for...

CEO

Arnon Rosenthal

IPO Date

Feb 7, 2019

Website

www.alector.com

Key Metrics TTM

Revenue

$21M

-79.1% YoY

Net Income

-$143M

EPS (Diluted)

-$1.39

Free Cash Flow

-$184M

Revenue / Share

$0.20

Gross Margin

89.3%

Operating Margin

-692.8%

Net Margin

-679.2%

FCF Margin

-874.7%

P/S

12.9x

P/E

—

Earnings Reports

Q1 2026

May 14, 2026

PENDING

FY 2025

Feb 25, 2026

$21M-79.1%EPS -$1.39

Q4 2025

Feb 25, 2026

$6M-88.5%EPS -$0.34

Q3 2025

Nov 6, 2025

$3M-78.8%EPS -$0.34

Q2 2025

Aug 7, 2025

$8M-47.8%EPS -$0.30

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$24M	-$29M	-$44M
Q2 22	$80M	$25M	$9M
Q3 22	$15M	-$33M	-$48M
Q4 22	$14M	-$40M	-$55M
Q1 23	$17M	-$35M	-$50M
Q2 23	$56M	$10M	-$4M
Q3 23	$9M	-$37M	-$51M
Q4 23	$15M	$13M	-$47M
Q1 24	$16M	$14M	-$44M
Q2 24	$15M	$13M	-$46M
Q3 24	$15M	$15M	-$48M
Q4 24	$54M	$8M	-$7M
Q1 25	$4M	$4M	-$45M
Q2 25	$8M	$8M	-$34M
Q3 25	$3M	$3M	-$38M
Q4 25	$6M	$4M	-$29M

Valuation

Quarter	P/S	P/E
Q1 22	5.2x	—
Q2 22	2.9x	24.4x
Q3 22	5.8x	—
Q4 22	5.0x	—
Q1 23	4.1x	—
Q2 23	5.0x	—
Q3 23	5.4x	—
Q4 23	7.0x	—
Q1 24	5.4x	—
Q2 24	7.5x	—
Q3 24	7.3x	—
Q4 24	1.7x	—
Q1 25	1.3x	—
Q2 25	1.7x	—
Q3 25	4.4x	—
Q4 25	7.4x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	$135M	$134M
Q2 22	-$57M	-$58M
Q3 22	-$49M	-$51M
Q4 22	-$49M	-$50M
Q1 23	-$49M	-$50M
Q2 23	-$43M	-$44M
Q3 23	-$47M	-$46M
Q4 23	-$46M	-$46M
Q1 24	-$61M	-$62M
Q2 24	-$63M	-$63M
Q3 24	-$51M	-$51M
Q4 24	-$55M	-$55M
Q1 25	-$61M	-$61M
Q2 25	-$49M	-$49M
Q3 25	-$33M	-$33M
Q4 25	-$42M	-$42M

Capital Expenditures

Quarter	CapEx
Q1 22	$692.0K
Q2 22	$744.0K
Q3 22	$2M
Q4 22	$766.0K
Q1 23	$1M
Q2 23	$1M
Q3 23	$94.0K
Q4 23	$233.0K
Q1 24	$533.0K
Q2 24	$337.0K
Q3 24	$212.0K
Q4 24	$173.0K
Q1 25	$20.0K
Q2 25	$10.0K
Q3 25	$11.0K
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	+495.5%	+20.9%
Q2 22	+1115.8%	+13.7%
Q3 22	-91.9%	+11.6%
Q4 22	+3.2%	+0.2%
Q1 23	-32.4%	-2.8%
Q2 23	-29.6%	-15.0%
Q3 23	-38.7%	-4.6%
Q4 23	+5.2%	-10.4%
Q1 24	-4.0%	-10.6%
Q2 24	-73.2%	+1.5%
Q3 24	+68.4%	+6.8%
Q4 24	+257.1%	-1.8%
Q1 25	-76.9%	-18.8%
Q2 25	-47.8%	-30.8%
Q3 25	-78.8%	-35.9%
Q4 25	-88.5%	-42.1%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$12M	48.8%
Q2 22	$12M	15.6%
Q3 22	$11M	72.5%
Q4 22	$11M	75.9%
Q1 23	$11M	66.3%
Q2 23	$10M	18.2%
Q3 23	$10M	110.4%
Q4 23	$12M	76.0%
Q1 24	$10M	64.9%
Q2 24	$10M	65.7%
Q3 24	$9M	58.9%
Q4 24	$10M	18.8%
Q1 25	$8M	227.3%
Q2 25	$7M	89.7%
Q3 25	$6M	196.4%
Q4 25	$5M	77.6%

OpEx Breakdown

Quarter	R&D	G&A
Q1 22	$53M	$16M
Q2 22	$58M	$16M
Q3 22	$52M	$14M
Q4 22	$57M	$15M
Q1 23	$54M	$15M
Q2 23	$55M	$14M
Q3 23	$54M	$13M
Q4 23	$45M	$15M
Q1 24	$43M	$14M
Q2 24	$44M	$14M
Q3 24	$48M	$16M
Q4 24	$49M	$15M
Q1 25	$34M	$15M
Q2 25	$28M	$14M
Q3 25	$31M	$12M
Q4 25	$31M	$13M

Revenue Segments

Quarter

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$455M	$414M	$869M
Q2 22	$172M	$637M	$809M
Q3 22	$184M	$574M	$758M
Q4 22	$154M	$559M	$713M
Q1 23	$196M	$474M	$669M
Q2 23	$132M	$499M	$630M
Q3 23	$102M	$487M	$589M
Q4 23	$75M	$474M	$549M
Q1 24	$73M	$490M	$562M
Q2 24	$48M	$456M	$503M
Q3 24	$37M	$420M	$457M
Q4 24	$33M	$380M	$413M
Q1 25	$38M	$317M	$355M
Q2 25	$45M	$263M	$307M
Q3 25	$77M	$215M	$291M
Q4 25	$66M	$190M	$256M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	82M	+0.7%	+3.4%
Q2 22	83M	+0.6%	+3.5%
Q3 22	83M	+0.0%	-3.1%
Q4 22	83M	+0.2%	+1.5%
Q1 23	83M	+0.4%	+1.2%
Q2 23	84M	+0.6%	+1.2%
Q3 23	84M	+0.4%	+1.6%
Q4 23	84M	+0.5%	+2.0%
Q1 24	94M	+11.2%	+12.9%
Q2 24	97M	+3.1%	+15.7%
Q3 24	97M	0.0%	+15.2%
Q4 24	98M	+1.7%	+16.5%
Q1 25	99M	+1.1%	+6.0%
Q2 25	100M	+1.0%	+3.8%
Q3 25	103M	+2.2%	+6.1%
Q4 25	103M	+0.4%	+4.8%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$117.7K	208
Q2 22	$383.9K	208
Q3 22	$71.4K	208
Q4 22	$52.9K	273
Q1 23	$60.6K	273
Q2 23	$205.9K	273
Q3 23	$33.4K	273
Q4 23	$62.3K	244
Q1 24	$65.1K	244
Q2 24	$61.8K	244
Q3 24	$62.9K	244
Q4 24	$227.9K	238
Q1 25	$15.4K	238
Q2 25	$33.1K	238
Q3 25	$13.7K	238
Q4 25	$31	200K

Revenue / Employee